

# Multiparametric In-vitro Cardiotoxicity Testing Market Set to Reach USD 166.5 Million by 2031 | TMR Study

*Rise in demand for effective and affordable techniques to assess the safety of drugs.*

WILMINGTON, DELAWARE, UNITED STATES, October 26, 2023

/EINPresswire.com/ -- [Multiparametric In-vitro Cardiotoxicity Testing Market](#) is expected to experience significant growth over the next decade. In 2021, the industry was valued at USD 44.5 million and is anticipated to expand rapidly at a compound annual growth rate of 13.9% from 2022 to 2031. Driven by rising drug development and safety testing requirements, the market size is forecasted to reach over USD 166.5 million by 2031.

□□□□□□□□ □ □□□□□□□□□□□□ □□□□□□  
□□ □□□□ □□□□□□ □□□□□□ @

[https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep\\_id=85319](https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85319)



Multiparametric in-vitro cardiotoxicity testing allows researchers to evaluate potential cardiac side effects of new drug candidates earlier in the development process before clinical trials. This helps pharmaceutical companies avoid costly late-stage failures and brings safer medications to market faster. As the biopharmaceutical industry continues to invest heavily in developing novel therapies for cardiovascular diseases, demand for advanced preclinical cardiotoxicity screening solutions is expected to rise substantially.

□□□□□□ □□□□□□□□

Growing drug development activities: The increasing number of drugs in the clinical

development pipeline is driving the need for advanced cardiotoxicity testing methods. Pharmaceutical companies are focusing on developing novel drugs to treat cardiovascular diseases, which requires thorough cardiotoxicity screening at the preclinical stage.

Stringent regulatory guidelines: Regulatory agencies have implemented stringent guidelines for drug safety evaluation. The FDA and EMA require comprehensive cardiac safety pharmacology studies before approval of new drug candidates. This is increasing the demand for reliable in-vitro cardiotoxicity screening assays.

Challenges in In-Vitro Screening

High costs associated: Multiparametric cardiotoxicity assays using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are expensive due to the high costs involved in culturing and maintaining the cells. This poses a challenge for small pharmaceutical companies with limited budgets.

Lack of standardization: There is a lack of standardized protocols and guidelines for in-vitro cardiotoxicity testing. Different cell types and assay conditions are used across industry and academia, making it difficult to compare results. This challenges the reliability and reproducibility of cardiotoxicity screening.

Market Research Report: [https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep\\_id=85319](https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85319)

Key Assays

Calcium Transient Assay

Cardiac Marker Detection

hERG Assay

Multi-ion Channel Assay

Others

Key Players

Contract Research Organizations (CROs)

Pharmaceutical and Biotech Companies

Others

□□□□□□□□ □□□□□□□□

Creative Bioarray

Agilent Technologies, Inc.

Hemogenix Inc.

Merck KGaA

Molecular Devices, LLC.

Miltenyi Biotec

FUJIFILM Cellular Dynamics

Enzo Life Sciences, Inc.

Axol Bioscience Ltd.

emka TECHNOLOGIES

Eurofins Discovery

Stemina Biomarker Discovery, Inc.

Evotec

□□□□ □□□ □□□□□? □□□ □□□ □□□□□□□□

[https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep\\_id=85319](https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85319)

□□□□□□□□□□ □□ □□□□□□ □□□□□□□□:

Overview of global Multiparametric In-vitro Cardiotoxicity Testing market

A detailed key player's analysis across regions

Analyses of global market trends, with historical data, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2031.

Insights into regulatory and environmental developments

Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Multiparametric In-vitro Cardiotoxicity Testing market

Major Company profiles

□□□ □□□□□□□□ □□□□ □□□□□□:

Essential evidential and historic data deriving the comparison of market scenario is offered.

Efficient analysis applied with the help of analytical tools ensuring precise data is provided for business experts.

Market dynamics and futuristic outlook offers the statistical growth rate along with market estimations.

Current market trends determining the constant change in customer behavior is provided.

A good balance of theoretical and statistical data encompassing the entire keyword market essentials.

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□ □□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□-

### [Cold Plasma Market](#)

Increase in adoption of atmospheric cold plasma in various applications due to an array of distinguishing properties can be ascribed to leading cold plasma market share of the segment in the past few years.

### [Sensor-Based Smart Catheters Market](#)

North America is anticipated to provide a significant share of sensor-based smart catheters market opportunities to regional and global manufacturers

Nikhil Sawlani

Transparency Market Research Inc.

+ +1 518-618-1030

[email us here](#)

Visit us on social media:

[Twitter](#)

[LinkedIn](#)

[YouTube](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/664427853>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.